Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.
about
A novel semi-supervised methodology for extracting tumor type-specific MRS sources in human brain dataConvex non-negative matrix factorization for brain tumor delimitation from MRSI data.Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification.Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trial.Non-negative matrix factorisation methods for the spectral decomposition of MRS data from human brain tumoursPediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified.Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age GroupsDistinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.Biology and management of ependymomas.Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signalingTherapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort AnalysisChromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymomaPediatric Brain Tumors: Current Knowledge and Therapeutic OpportunitiesTreatment implications of posterior fossa ependymoma subgroups.The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases.Vascular patterns of brain tumors.Spinal cord ependymomas in children and adolescents.Current and evolving knowledge of prognostic factors for pediatric ependymomas.Prognostic marker analysis in pediatric intracranial ependymomas.Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.Posterior fossa ependymoma: current insights.Advances in Management of Pediatric Ependymomas.Pediatric Ependymoma.Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives.Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.The new WHO 2016 classification of brain tumors-what neurosurgeons need to know.Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas.Evaluation of chromosome 1q gain in intracranial ependymomas.Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma.Toward an integrated histomolecular diagnosis of supratentorial ependymoma.Molecular dissection of ependymomas.Nestin expression identifies ependymoma patients with poor outcome.Apparent diffusion coefficient of pediatric cerebellar tumors: a biomarker of tumor grade?Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression.
P2860
Q30000658-68FCC845-ED54-4858-9C0D-DC70775A4D57Q30575323-204724D6-F00E-484D-9731-C1B04686CC94Q30613404-B53AF799-1958-4E93-9F19-09F262138A36Q33803137-CCE40819-3154-4E3B-BD57-EB5A01AE60B9Q33993483-51FA4337-D99E-428E-856C-41CDDD5C1D22Q34188634-C2CF1850-5D22-4532-9AD8-AC253A7E1D68Q35754390-EC35C731-018E-4D9C-81B4-90AAF29F39FAQ35815310-872F530C-E094-4EFD-B9E0-1690F1FDF81BQ36070798-80C4D46C-FFB0-43E8-A7C4-AA14C02796D6Q36461766-2E7936D4-49EE-4474-99F2-F1BB07DC375BQ36560149-D34118A8-EC90-4BD6-B06E-95F14CF411E7Q36977704-28DF0920-5891-43AF-93FC-8F3E2919FB15Q36977707-6B8FA367-2B19-47ED-97BA-E069D277B30BQ37130238-CA98BFD3-C4C6-4A3C-AFF5-E846BAF080B7Q37196135-2FB116B7-1C1B-462A-B481-D81C685267DDQ37213305-71E83A1A-938C-4CD8-9D17-094FA437832AQ37416967-405B73A2-0844-41C2-A820-F929E4C1FE30Q37553466-449D8499-EF4B-44B7-8C23-7AB2A95A2E44Q37641698-03134D1F-178F-42C5-A026-1D60DAC82A2AQ37727557-D9C6D0F9-A015-4C53-BEEC-9F26F9970E7FQ37921513-9F86B777-73EB-4452-8118-D25482958958Q38041984-73104461-A7F2-458F-AB0F-92D9448B9A5CQ38081982-1ED5ADF9-8E4A-4FA1-8ECF-AFD39D90152DQ38309196-C1CA6D42-66E6-4BD0-8B95-6A06CEC579E9Q38399886-F265B5B6-96AB-49FC-BD39-9C63FA6A431EQ38583252-C26C212C-D7A1-469C-AFA3-51299BB9E308Q38586580-50FE51BF-7478-44A0-8BB2-7E7042D5D795Q38616800-52569AFE-E20A-401F-A2B6-FA463FD7DB93Q38681915-40F51FEC-CAFB-4744-9779-9593B10A4D50Q38858546-6AE89ACA-6D9B-40AB-859F-CEEF9C473FE9Q38865516-B1820E59-B917-4A74-A3AE-309E04B8C7C6Q39091307-8F6B07FB-B538-4282-ADBD-047D96670313Q39316156-2FA5AD87-B926-415C-AB49-3B4F646C7D48Q40150706-E4B81A2D-4607-44F8-B25F-2D73456E16CCQ40190070-B721A834-9E79-4D31-B281-63CA9FBCDF59Q42738552-9ABD63BA-2B83-4D84-B4BF-EE71B0E4BF90Q43141039-46A60CC1-E4D2-408B-BB46-E2BA99CCF3D0Q43662312-2A69E7DD-C474-4654-8619-03EAC0AF3936Q44251430-A1676C01-FCD0-4F27-A39A-F47613A14E05Q44856848-5E967D00-5CD8-44EB-876D-8A158479FFA6
P2860
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Histopathological grading of p ...... nce in European trial cohorts.
@ast
Histopathological grading of p ...... nce in European trial cohorts.
@en
type
label
Histopathological grading of p ...... nce in European trial cohorts.
@ast
Histopathological grading of p ...... nce in European trial cohorts.
@en
prefLabel
Histopathological grading of p ...... nce in European trial cohorts.
@ast
Histopathological grading of p ...... nce in European trial cohorts.
@en
P2093
P2860
P50
P356
P1476
Histopathological grading of p ...... nce in European trial cohorts.
@en
P2093
David W Ellison
Didier Frappaz
Giangaspero Felice
Godfraind Catherine
James M Boyett
Richard G Grundy
Torsten Pietsch
P2860
P356
10.1186/1477-5751-10-7
P577
2011-05-31T00:00:00Z